Flagship's $3.37bn Fund To Grow First-In-Category Firms
Also Building Preemptive Medicine Division
Executive Summary
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
You may also be interested in...
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
IP Waiver Proposal Won’t Hold Back Moderna’s Rise
While White House support for an intellectual property waiver has been cheered by access campaigners, Moderna said it won’t help solve the pandemic’s big vaccine production challenges any time soon.